Department of Internal Medicine III, University of Munich, Grosshadern, Germany.
Curr Hematol Malig Rep. 2011 Dec;6(4):207-15. doi: 10.1007/s11899-011-0099-5.
Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include prolongation of survival and effective palliation of symptoms while limiting the duration of therapy to minimize adverse effects and reduce costs. Multiple rounds of treatment over many years characterize the clinical course for most patients with FL. Rituximab in combination with chemotherapy has been shown to improve overall survival in patients with FL compared with chemotherapy alone. Rituximab maintenance further improves disease control in patients with FL after a successful induction therapy in both first-line treatment and relapse. Consolidation with radioimmunotherapy is an innovative treatment approach to increase rates of complete remission and duration of remission. Here we summarize the data from actual trials and the resulting treatment indications.
滤泡性淋巴瘤（FL）是最常见的惰性淋巴瘤，通常在晚期发病。目前的可用疗法通常不能达到治愈的效果，但自抗 CD20 单克隆抗体免疫疗法问世以来，FL 的生存率已有所提高。治疗的目标包括延长生存时间和有效缓解症状，同时限制治疗的持续时间以最大限度地减少不良反应并降低成本。大多数 FL 患者的临床病程特征是多年来多次治疗。与单独化疗相比，利妥昔单抗联合化疗已显示可改善 FL 患者的总生存率。在一线治疗和复发后成功诱导治疗后，利妥昔单抗维持治疗进一步改善了 FL 患者的疾病控制。放射性免疫疗法巩固是一种增加完全缓解率和缓解持续时间的创新治疗方法。在此，我们总结了实际试验的数据和由此产生的治疗指征。
